In a report released yesterday, Patrick B Donnelly from Citi maintained a Buy rating on Qiagen (QGEN – Research Report), with a price target of $55.00.
Patrick B Donnelly has given his Buy rating due to a combination of factors including Qiagen’s strong financial performance and positive growth outlook. The company reported first-quarter 2025 sales and earnings per share that exceeded initial market expectations, with significant year-over-year growth in key product lines such as QuantiFERON and QIAstat-Dx.
Management’s reaffirmation of their growth and earnings guidance for the full year, along with an increase in expected earnings per share, further supports the positive outlook. Additionally, Qiagen’s ability to navigate potential challenges, such as recent US tariffs, while maintaining robust revenue growth, underpins the confidence in the company’s future performance.
According to TipRanks, B Donnelly is a 2-star analyst with an average return of 0.0% and a 43.64% success rate. B Donnelly covers the Healthcare sector, focusing on stocks such as Danaher, Agilent, and Icon.
In another report released yesterday, Bank of America Securities also maintained a Buy rating on the stock with a $50.00 price target.